tiprankstipranks
Trending News
More News >

Quoin Pharmaceuticals announces EMA grants ODD for QRX003

Quoin Pharmaceuticals (QNRX) announces that it has been granted Orphan Drug Designation, ODD, in Europe by the European Medicines Agency, EMA, for its lead product QRX003 in Netherton Syndrome. Orphan Drug Designation in Europe affords the Company incentive benefits including scientific advice on study protocols, various fee reductions and access to EU grants. If approved, QRX003 will be granted 10 years of market exclusivity in Europe for the treatment of Netherton Syndrome.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1